Category: Latest News
-
BTCS Shares Jump After Securing $10M Convertible Note Deal to Boost Ethereum Strategy
Shares of BTCS Inc (NASDAQ:BTCS) soared 11% after the blockchain-focused firm announced a $10 million convertible note financing agreement with ATW Partners LLC, further reinforcing its aggressive Ethereum investment strategy. The company said the newly arranged funding adds to its liquidity reserves, pushing the combined market value of its Ethereum holdings, cash, and other liquid…
-
Mobilicom Shares Climb After Locking in $1.4 Million U.S. Drone Orders
Mobilicom Ltd ADR (NASDAQ:MOB) saw its stock jump 11.3% after the company announced it secured roughly $1.4 million in new orders from a major U.S.-based drone manufacturer. The cybersecurity and drone tech company said the orders came from an existing client described as a Tier-1 drone producer with more than $5 billion in annual revenue.…
-
Thomson Reuters Shares Edge Higher After Joining Nasdaq-100 Index
Thomson Reuters Corp (NASDAQ:TRI) saw a modest 0.5% increase in premarket trading Monday following an announcement from Nasdaq that the company will be added to the Nasdaq-100 Index, one of the most prominent benchmarks in U.S. equity markets. The financial data and media company is set to replace ANSYS Inc. (NASDAQ:ANSS) in the Nasdaq-100 Index…
-
Oruka Therapeutics Shares Climb After FDA Greenlights Psoriasis Drug Trial
Oruka Therapeutics Inc (NASDAQ:ORKA) saw its stock rise 6.6% after revealing that the U.S. Food and Drug Administration (FDA) has approved its investigational new drug (IND) application to begin a Phase 2a clinical trial of its psoriasis drug, ORKA-001. The study, named EVERLAST-A, will test Oruka’s extended-duration anti-IL-23p19 antibody in roughly 80 patients suffering from…
-
Sarepta Shares Drop as FDA Suspends Gene Therapy Trials for Muscular Dystrophy
Shares of Sarepta Therapeutics Inc (NASDAQ:SRPT) plunged 10% after the company disclosed that the U.S. Food and Drug Administration (FDA) has imposed a clinical hold on several of its gene therapy programs targeting limb girdle muscular dystrophy (LGMD). The hold impacts a series of Sarepta’s experimental therapies, including SRP-9003, SRP-9004, SRP-6004, and SRP-9005. Notably, Sarepta…
-
SAB Biotherapeutics Shares Jump 33% After Securing $175M in Oversubscribed Private Placement
SAB Biotherapeutics Inc (NASDAQ:SABS) saw its stock surge by 33% following the announcement of a $175 million private placement backed by a mix of strategic and institutional investors. The oversubscribed financing round was led by pharmaceutical giant Sanofi (NASDAQ:SNY) and joined by new investors such as RA Capital Management, Commodore Capital, Vivo Capital, and Blackstone’s…
-
U.S. Stocks Edge Higher as Investors Watch Earnings and Tariff Developments
U.S. stocks moved up slightly on Monday morning as investors looked ahead to a busy week of second-quarter earnings reports, with major firms set to announce results. By 9:35 a.m. ET: Markets had stalled near record highs last Friday amid reports that President Trump is pushing for new tariffs of at least 15% to 20%…
-
Dow Jones, S&P, Nasdaq, Wall Street Set for Higher Open Amid Trade Optimism and Earnings Watch
U.S. markets are on track for a higher open Monday, as investors digest growing optimism surrounding trade negotiations and brace for a wave of major corporate earnings. Futures linked to the Dow Jones Industrial Average, Nasdaq, and S&P 500 are pointing toward early gains, rebounding from a muted close last Friday when stocks lacked direction…
-
Helius Medical Technologies Surges 70% on Promising Stroke Therapy Trial Results
July 21, 2025 — Helius Medical Technologies (NASDAQ:HSDT) saw its stock soar more than 70% in pre-market trading Monday after reporting strong clinical results for its Portable Neuromodulation Stimulator (PoNS) Stroke Registrational Program (SRP). The neurotechnology company announced that a double-blind, randomized clinical trial for the PoNS SRP successfully met its primary endpoint. The trial…
-
DeFi Development Corp. stock surges as Solana holdings approach 1 million
Shares of DeFi Development Corp. (NASDAQ:DFDV) climbed 10.6% after the company revealed it is on the verge of holding 1 million Solana (SOL) tokens, with its balance now totaling 999,999 SOL and equivalents — a position worth approximately $181 million. Between July 14 and July 20, the firm acquired 141,383 SOL at an average cost…